Summary of current human models for MA4+ B-ALL
Ontogeny stage . | Cell type . | Phenotype . | Leukemic cooperation with FLT3/RAS* mutants . | Reference . |
---|---|---|---|---|
Fetal-HSPC* | NA | — | NA | — |
Embryonic HSPC | hESC-derived hematopoietic cells | Enhances early hemato-endothelial specification | No | 117 |
Skew toward endothelial vs hematopoietic fate | ||||
118 | ||||
Neonatal HSPC | CB-derived CD34+ HSPCs | Proliferation coupled to survival advantage | No | 116 |
Enhanced engraftment and clonogenic potential | ||||
119 |
Ontogeny stage . | Cell type . | Phenotype . | Leukemic cooperation with FLT3/RAS* mutants . | Reference . |
---|---|---|---|---|
Fetal-HSPC* | NA | — | NA | — |
Embryonic HSPC | hESC-derived hematopoietic cells | Enhances early hemato-endothelial specification | No | 117 |
Skew toward endothelial vs hematopoietic fate | ||||
118 | ||||
Neonatal HSPC | CB-derived CD34+ HSPCs | Proliferation coupled to survival advantage | No | 116 |
Enhanced engraftment and clonogenic potential | ||||
119 |
Unpublished preliminary data.